CN106488773B - Apc类似物用于创伤愈合的用途 - Google Patents

Apc类似物用于创伤愈合的用途 Download PDF

Info

Publication number
CN106488773B
CN106488773B CN201580025422.7A CN201580025422A CN106488773B CN 106488773 B CN106488773 B CN 106488773B CN 201580025422 A CN201580025422 A CN 201580025422A CN 106488773 B CN106488773 B CN 106488773B
Authority
CN
China
Prior art keywords
apc
wound
skin
wounds
wound healing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580025422.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN106488773A (zh
Inventor
薛妹朗
克里斯托弗·约翰·杰克逊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ZZ Biotech LLC
Original Assignee
ZZ Biotech LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2014901397A external-priority patent/AU2014901397A0/en
Application filed by ZZ Biotech LLC filed Critical ZZ Biotech LLC
Publication of CN106488773A publication Critical patent/CN106488773A/zh
Application granted granted Critical
Publication of CN106488773B publication Critical patent/CN106488773B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4866—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0061—Use of materials characterised by their function or physical properties
    • A61L26/0066—Medicaments; Biocides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0061—Use of materials characterised by their function or physical properties
    • A61L26/0076—Sprayable compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0061—Use of materials characterised by their function or physical properties
    • A61L26/008—Hydrogels or hydrocolloids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Materials Engineering (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
CN201580025422.7A 2014-04-16 2015-04-16 Apc类似物用于创伤愈合的用途 Active CN106488773B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AU2014901397 2014-04-16
AU2014901397A AU2014901397A0 (en) 2014-04-16 Treatment of abnormal cutaneous scarring
AU2014902900A AU2014902900A0 (en) 2014-07-25 Use of APC analogue for wound healing
AU2014902900 2014-07-25
PCT/AU2015/050177 WO2015157822A1 (en) 2014-04-16 2015-04-16 Use of apc analogue for wound healing

Publications (2)

Publication Number Publication Date
CN106488773A CN106488773A (zh) 2017-03-08
CN106488773B true CN106488773B (zh) 2020-02-11

Family

ID=54323284

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580025422.7A Active CN106488773B (zh) 2014-04-16 2015-04-16 Apc类似物用于创伤愈合的用途

Country Status (11)

Country Link
US (3) US20170035862A1 (enExample)
EP (1) EP3131572B1 (enExample)
JP (2) JP6873387B2 (enExample)
CN (1) CN106488773B (enExample)
AU (1) AU2015246656B2 (enExample)
CA (1) CA2946032C (enExample)
DK (1) DK3131572T3 (enExample)
ES (1) ES2890623T3 (enExample)
PL (1) PL3131572T3 (enExample)
PT (1) PT3131572T (enExample)
WO (1) WO2015157822A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2662564C2 (ru) 2012-07-04 2018-07-26 ЗЗ Байотек ЛЛС Лечение воспалительных заболеваний кожи
EP3137102B1 (en) 2014-04-16 2021-07-14 ZZ Biotech LLC Apc for use in the treatment of abnormal cutaneous scarring
CN107619437B (zh) * 2017-11-07 2019-08-13 昆明医科大学 一种皮肤创伤修复肽whpp-oa1及其提纯方法与应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775624A (en) 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
US5516650A (en) 1985-06-27 1996-05-14 Zymogenetics, Inc. Production of activated protein C
US4959318A (en) 1985-06-27 1990-09-25 Zymogenetics, Inc. Expression of protein C
EP0380508A4 (en) 1987-05-18 1991-04-03 Integrated Genetics, Inc. Improved protein c molecules and method for making and activating same
US5084274A (en) 1987-11-17 1992-01-28 Scripps Clinic And Research Foundation Inhibition of arterial thrombotic occlusion or thromboembolism
US4981952A (en) 1988-10-04 1991-01-01 Eli Lilly And Company Method for the purification of vitamin K-dependent proteins
US5093117A (en) 1989-01-24 1992-03-03 Baxter International Inc. Compositions and method for the treatment or prophylaxis of sepsis or septic shock
AT402260B (de) 1990-08-16 1997-03-25 Immuno Ag Protein c-hältige pharmazeutische präparation
US5571786A (en) 1990-08-16 1996-11-05 Immuno Aktiengesellschaft Use of protein C or the activation peptide of protein C for preparing a pharmaceutical preparation
AT397615B (de) 1991-05-14 1994-05-25 Immuno Ag Arzneimittel enthaltend protein c
WO1993009807A1 (en) 1991-11-18 1993-05-27 The Scripps Research Institute Methods of inhibiting thrombosis via elevation of circulating endogenous activated protein c levels
MY110664A (en) 1992-05-21 1999-01-30 Lilly Co Eli Protein c derivatives
DE4239150A1 (de) 1992-11-20 1994-05-26 Thomae Gmbh Dr K O-Acyl-4-phenyl-cyclohexanole, deren Salze, diese Verbindungen enthaltende Arzneimittel und deren Verwendung sowie Verfahren zu ihrer Herstellung
JP3043558B2 (ja) 1993-10-29 2000-05-22 財団法人化学及血清療法研究所 ヒト活性化プロテインｃ調製物及びその製法
WO1995030429A1 (en) 1994-05-04 1995-11-16 Board Of Trustees Of The University Of Arkansas Novel ophthalmologic uses of protein c
BR9809304B1 (pt) 1997-04-28 2011-02-08 formulação liofilizada estável, processo para preparação da mesma, bem como forma de dosagem unitária.
HUP0001237A3 (en) 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders
EP1255556B1 (en) 2000-02-04 2011-04-06 The Scripps Research Institute Neuroprotective, antithrombotic and anti-inflammatory uses of activated protein c (apc)
EP1263943A1 (en) 2000-02-11 2002-12-11 Eli Lilly & Company Protein c derivatives
CA2404231A1 (en) 2000-03-28 2001-10-04 Eli Lilly And Company Methods of treating diseases with activated protein c
AU2002210388B2 (en) 2000-10-18 2006-11-23 Perseid Therapeutics Llc Protein C or activated protein C like molecules
EP1404412B1 (en) 2001-06-13 2012-03-21 The University of Sydney Protein C for wound healing
AU2003275948A1 (en) 2002-11-06 2004-06-07 Novo Nordisk A/S Pharmaceutical composition comprising a tissue factor antagonist and protein c polypeptides
DK1477166T3 (da) 2003-04-28 2006-12-11 Biofrontera Bioscience Gmbh Anvendelse af riluzoler kombineret med egnede hjælpe- og tilsætningsstoffer til behandling af sygdomme, som er kendetegnet ved en hyperproliferation af keratinocytter, navnlig neurodermitis og psoriasis
JP4986618B2 (ja) * 2003-07-08 2012-07-25 ザ スクリプス リサーチ インスティチュート 通常の細胞保護活性を有するが抗凝固活性が低下した活性化プロテインｃ変異体
US9192657B2 (en) 2003-07-08 2015-11-24 The Scripps Research Institute Activated protein C variants with normal cytoprotective activity but reduced anticoagulant activity
US20070224150A1 (en) 2005-03-24 2007-09-27 Yongji Chung Growth factor for hair and skin treatment
BRPI0611710A2 (pt) 2005-06-24 2011-12-20 Drugrecure Aps administração às vias aéreas de inibidor do passo de fator tissular, em condições inflamatórias que afetam o trato respiratório
GR1005700B (el) 2006-09-01 2007-10-22 (40%) ����� �������� Τροπος αντιμετωπισης της 1ης φασης του εγκαυματοσσε μη σηπτικους ασθενεις με συνεχη ενδοφλεβια χορηγηση ενεργοποιημενης πρωτεινης-c για 48 ωρες με στοχο τη μειωση της τελικης εγκαυματικης βλαβης καιαυξηση της ταχυτητας επουλωσης κατα τα πρωτα επτα μετεγκαυματικα 24ωρα
EP2078074A4 (en) * 2006-10-31 2011-09-28 Scripps Research Inst DOSAGE SCHEME OF ACTIVATED PROTEIN C AND ITS VARIANTS WITH REDUCED ANTICOAGULANT ACTIVITY
GB0724231D0 (en) 2007-12-12 2008-01-30 Renono Ltd Methods for inhibiting scarring
ES2316312B1 (es) 2008-06-20 2010-02-08 Ignacio Umbert Millet Composicion farmaceutica dermatologica para el tratamiento de patologias de inflamacion de la piel, tales como por ejemplo dermatitis, dermatitis atopica, vitiligo, alopecia areata, acne, psoriasis y prurito,y combinaciones de las mismas.
EP2157176A1 (en) 2008-08-20 2010-02-24 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Protein C Variants
CN101912450A (zh) 2010-09-01 2010-12-15 吴业刚 一种治疗脚气皮炎的中西药组合物及其制备方法
RU2662564C2 (ru) * 2012-07-04 2018-07-26 ЗЗ Байотек ЛЛС Лечение воспалительных заболеваний кожи
EP3137102B1 (en) 2014-04-16 2021-07-14 ZZ Biotech LLC Apc for use in the treatment of abnormal cutaneous scarring

Also Published As

Publication number Publication date
EP3131572A1 (en) 2017-02-22
CN106488773A (zh) 2017-03-08
PL3131572T3 (pl) 2022-02-07
WO2015157822A1 (en) 2015-10-22
EP3131572B1 (en) 2021-07-14
CA2946032C (en) 2022-06-14
US20200000890A1 (en) 2020-01-02
EP3131572A4 (en) 2017-12-20
ES2890623T3 (es) 2022-01-20
JP6873387B2 (ja) 2021-05-19
US20170035862A1 (en) 2017-02-09
US12214024B2 (en) 2025-02-04
JP2020100648A (ja) 2020-07-02
DK3131572T3 (da) 2021-10-11
AU2015246656A1 (en) 2016-11-03
US20180243383A1 (en) 2018-08-30
JP2017513945A (ja) 2017-06-01
AU2015246656B2 (en) 2020-06-18
CA2946032A1 (en) 2015-10-22
PT3131572T (pt) 2021-09-24

Similar Documents

Publication Publication Date Title
US12128086B2 (en) Formulations and methods of use for alpha connexin c-terminal (ACT) peptides
JP6846063B2 (ja) 異常な皮膚瘢痕化の治療
US12214024B2 (en) Use of APC analogue for wound healing
CN100509055C (zh) 使用凝血酶衍生的缩氨酸治疗慢性真皮溃疡
Fife et al. Thrombin peptide Chrysalin® stimulates healing of diabetic foot ulcers in a placebo‐controlled phase I/II study
CN113226350B (zh) 皮肤病治疗剂
HK1230520B (zh) Apc类似物用於创伤癒合的用途
HK1230520A1 (en) Use of apc analogue for wound healing
RU2799211C2 (ru) Средство для лечения дерматологических заболеваний
HK40047629A (zh) 皮肤病治疗剂
HK1235306B (zh) 治疗异常皮肤瘢痕形成

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1230520

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant